ArticleIDCases2026
Successful treatment of severe influenza-associated pulmonary aspergillosis with invasive tracheobronchitis and bronchial asthma using combination antifungals and omalizumab: A case report.
Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza-associated pulmonary aspergillosis (IAPA) is a secondary pulmonary aspergillosis following influenza, predominantly occurring in critically ill influenza patients requiring intensive care unit admission. It carries a high mortality rate, particularly in patients with invasive Aspergillus tracheobronchitis (IATB), where the fatality rate can reach up to 90%. This article reports a case of severe IAPA complicated by IATB and bronchial asthma and successfully treated with combination therapy of high dose antifungals and biologic. The patient had failed multiple antifungal therapies at another hospital and rapidly progressed to respiratory failure, necessitating endotracheal intubation before being transferred to our institution. Through a treatment regimen comprising a loading dose of caspofungin, triazole antifungals, inhaled amphotericin B, and omalizumab, the patient was successfully weaned off mechanical ventilation, extubated, and eventually discharged in improved condition. During treatment, voriconazole blood concentration was found to be extremely low, and CYP2C19 genotyping suggested a rare rapid/ultrarapid metabolizer variant.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.